It may well be that only the subset of patients with mTOR pathway over-expression would benefit from immunosuppression protocols based on mTOR inhibitors, thus allowing for a true personalized immunosuppression in LT patients with HCC. Here, MTOR is linked to hepatocellular carcinoma.